Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969358 | 0.84 | FNTA (0.41) | FNTAFNTB | |
| SCHEMBL14289895 | 0.84 | FNTA (0.58) | FNTAFNTB | |
| SCHEMBL13611706 | 0.84 | FNTA (0.58) | FNTAFNTB | |
| SCHEMBL6176740 | 0.84 | FNTA (0.58) | FNTAFNTB | |
| SCHEMBL14416063 | 0.81 | FNTA (0.40) | FNTAFNTB | |
| SCHEMBL13935172 | 0.81 | FNTA (0.40) | FNTAFNTB | |
| SCHEMBL13604336 | 0.80 | FNTA (0.55) | FNTAFNTB | |
| SCHEMBL7000604 | 0.78 | FNTA (0.42) | FNTAFNTB | |
| SCHEMBL4966335 | 0.78 | OPRL1 (0.44) | FNTAFNTB | |
| SCHEMBL14102072 | 0.78 | MEN1 (0.58) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416108-B2 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416108-B2 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416108-B2 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2097387-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2097387-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2153832-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2343069-B1 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2343069-B1 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20150105354-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105354-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | US | disclosed |
| EP-0270818-B1 | Benzo(5,6)cycloheptapyridines, compositions and method of use | SCHERING CORP (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0396083-B1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORP (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5151423-A | Antiinflammatory agents or antiallergens | SCHERING CORPORATION (US) | 1992-09-29 | — | — | US | disclosed |
| EP-0471750-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1992-02-26 | — | — | EP | disclosed |
| US-5089496-A | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies | SCHERING CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| WO-1990013548-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1990-11-15 | — | — | WO | disclosed |
| EP-0396083-A1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORPORATION (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0330673-A1 | BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0270818-A1 | Benzo(5,6)cycloheptapyridines, compositions and method of use | SCHERING CORPORATION (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988003138-A1 | BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105354-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | PRSS1, BCHE, CTSZ | FNTA 4678/4885FNTB 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.